Capecitabine combined with TACE for advanced liver cancer.
- Author:
Li LI
1
;
Feng SUN
;
Ai-jun CHEN
;
Xiao-yan LI
;
Ming-dao HU
;
Jiang-hua RAN
;
Ji-hong TANG
Author Information
- Publication Type:Journal Article
- MeSH: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; administration & dosage; Capecitabine; Chemoembolization, Therapeutic; Combined Modality Therapy; Deoxycytidine; administration & dosage; analogs & derivatives; Drug Administration Schedule; Female; Fluorouracil; analogs & derivatives; Humans; Liver Neoplasms; pathology; therapy; Male; Middle Aged; Mitomycin; administration & dosage
- From: Chinese Journal of Oncology 2004;26(9):565-566
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo evaluate the clinical efficacy of capecitabine combined with transcatheter arterial chemoembolization (TACE) for advanced liver cancer.
METHODSForty-nine patients with liver cancer were retrospectively divided into two groups: Treatment group, on the basis of TACE, 23 patients received oral capecitabine at 2500 mg/m(2), twice-daily for 14 days followed by 7-day rest period and repeated in every three week intervals for more than two cycles. Control group, 26 patients received TACE only at 2-month intervals for at least two cycles.
RESULTSIn capecitabine and TACE group: there were 1 CR, 14 PR, 5 SD and 3 PD; the overall response rate was 65.2%; the AFP and tumor reduction rates were 68.8% and 73.9%; the median survival time was 11.9 months. In the TACE only group: there were 0 CR, 7 PR, 12 SD and 7 PD; the overall response rate was 26.9%; the AFP and tumor reduction rates were 31.6 % and 30.8%; the median survival time was 8.3 months. The most common side-effects of capecitabine were hand-foot syndrome and diarrhea.
CONCLUSIONCapecitabine combined with TACE is safe and effective for advanced liver cancer.
